Biomerica (BMRA) to Post Earnings on Monday

Biomerica (NASDAQ:BMRA) is anticipated to post its results after the market closes on Monday, April 13th. Analysts expect Biomerica to post earnings of ($1.20) per share and revenue of $3.6290 million for the quarter.

Biomerica (NASDAQ:BMRA) last released its quarterly earnings results on Wednesday, January 14th. The company reported ($0.45) EPS for the quarter. Biomerica had a negative net margin of 90.29% and a negative return on equity of 83.73%. The business had revenue of $1.21 million during the quarter.

Biomerica Price Performance

Shares of Biomerica stock opened at $2.17 on Monday. The stock has a market capitalization of $6.55 million, a price-to-earnings ratio of -2.33 and a beta of 0.20. Biomerica has a twelve month low of $1.87 and a twelve month high of $4.88. The company has a 50-day simple moving average of $2.17 and a two-hundred day simple moving average of $2.47.

Institutional Investors Weigh In On Biomerica

An institutional investor recently raised its position in Biomerica stock. DRW Securities LLC increased its stake in shares of Biomerica, Inc. (NASDAQ:BMRA) by 62.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,925 shares of the company’s stock after buying an additional 6,533 shares during the quarter. DRW Securities LLC owned about 0.56% of Biomerica worth $43,000 at the end of the most recent reporting period. Institutional investors own 22.28% of the company’s stock.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.